[go: up one dir, main page]

LU91528I2 - "Etravirine sous toutes formes couvertes par le brevet de base" - Google Patents

"Etravirine sous toutes formes couvertes par le brevet de base"

Info

Publication number
LU91528I2
LU91528I2 LU91528C LU91528C LU91528I2 LU 91528 I2 LU91528 I2 LU 91528I2 LU 91528 C LU91528 C LU 91528C LU 91528 C LU91528 C LU 91528C LU 91528 I2 LU91528 I2 LU 91528I2
Authority
LU
Luxembourg
Prior art keywords
etravirine
basic patent
form covered
covered
basic
Prior art date
Application number
LU91528C
Other languages
English (en)
Other versions
LU91528I9 (fr
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91528(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LU91528I2 publication Critical patent/LU91528I2/fr
Publication of LU91528I9 publication Critical patent/LU91528I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LU91528C 1998-11-10 2009-02-18 "Etravirine sous toutes formes couvertes par le brevet de base" LU91528I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (fr) 1998-11-10 1999-09-24 Pyrimidines inhibant la replication du vih

Publications (2)

Publication Number Publication Date
LU91528I2 true LU91528I2 (fr) 2009-04-20
LU91528I9 LU91528I9 (fr) 2019-01-02

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91528C LU91528I2 (fr) 1998-11-10 2009-02-18 "Etravirine sous toutes formes couvertes par le brevet de base"

Country Status (41)

Country Link
US (5) US6878717B2 (fr)
EP (2) EP1002795B1 (fr)
JP (1) JP3635238B2 (fr)
KR (1) KR100658489B1 (fr)
CN (1) CN1214013C (fr)
AP (1) AP1683A (fr)
AR (1) AR024227A1 (fr)
AT (2) ATE455107T1 (fr)
AU (2) AU762523C (fr)
BG (1) BG65103B1 (fr)
BR (1) BRPI9915552B8 (fr)
CA (1) CA2350801C (fr)
CY (1) CY2008021I1 (fr)
CZ (1) CZ301367B6 (fr)
DE (3) DE69941934D1 (fr)
DK (1) DK1002795T3 (fr)
EA (1) EA004049B1 (fr)
EE (1) EE05086B1 (fr)
ES (2) ES2338760T3 (fr)
FR (1) FR09C0004I2 (fr)
HK (1) HK1048817B (fr)
HR (2) HRP20080359B1 (fr)
HU (2) HU227453B1 (fr)
ID (1) ID28376A (fr)
IL (2) IL143023A0 (fr)
LT (1) LTC1002795I2 (fr)
LU (1) LU91528I2 (fr)
MY (1) MY121108A (fr)
NL (1) NL300373I2 (fr)
NO (3) NO318801B1 (fr)
NZ (1) NZ511116A (fr)
OA (1) OA11674A (fr)
PL (1) PL204427B1 (fr)
PT (1) PT1002795E (fr)
SI (1) SI1002795T1 (fr)
SK (2) SK287269B6 (fr)
TR (1) TR200101306T2 (fr)
TW (1) TWI238161B (fr)
UA (1) UA70966C2 (fr)
WO (1) WO2000027825A1 (fr)
ZA (1) ZA200103769B (fr)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100658489B1 (ko) * 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
CA2386218A1 (fr) 1999-10-07 2001-04-12 Amgen Inc. Inhibiteurs de triazine kinase
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
ES2542326T3 (es) * 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
CN1302418C (zh) * 2000-11-01 2007-02-28 斯雷普内姆斯·Com公司 集成注册机构的互联网域名获取系统
ATE420077T1 (de) 2001-05-29 2009-01-15 Bayer Schering Pharma Ag Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003032994A2 (fr) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
PL369259A1 (en) 2001-11-01 2005-04-18 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003209727B2 (en) 2002-03-13 2008-10-16 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EA008244B1 (ru) * 2002-05-03 2007-04-27 Янссен Фармацевтика Н.В. Полимерные микроэмульсии
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
HRP20050104B1 (hr) * 2002-08-09 2014-02-14 Janssen Pharmaceutica N.V. Postupci za pripremu 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
EP2422772A3 (fr) * 2002-09-20 2012-04-18 Alpharma, Inc. Séquestration de sous-unité et compositions et procédés associés
PL377795A1 (pl) * 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CN102151270A (zh) 2003-02-07 2011-08-17 詹森药业有限公司 预防hiv感染的嘧啶衍生物
AP2005003365A0 (en) * 2003-02-07 2005-09-30 Janssen Pharmaceutica Nv Hiv inhibiting 1, 2, 4-triazines.
DE602004021472D1 (en) * 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US20060172010A1 (en) 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
BRPI0414791A (pt) * 2003-09-25 2006-11-21 Janssen Pharmaceutica Nv derivados de purina inibidores da replicação do hiv
US8099262B2 (en) 2004-03-02 2012-01-17 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (fr) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
JP5031564B2 (ja) 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
CA2573976C (fr) * 2004-09-30 2014-04-29 Tibotec Pharmaceuticals Ltd. 5-carbo- ou heterocycliques pyrimidines substituees inhibitrices de vih
WO2006035067A2 (fr) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. 5-heterocyclyl-pyrimidines inhibitrices du vih
RU2410379C2 (ru) * 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
CA2577588C (fr) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Derives de pyrimidine bicycliques inhibant le vih
US20060106043A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and etravirine
EP1814878B1 (fr) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Composes de spiro-2, 4-pyrimidinediamine et leurs utilisations
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
BRPI0607214B8 (pt) * 2005-01-27 2021-05-25 Janssen R & D Ireland derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
RU2405780C2 (ru) 2005-02-16 2010-12-10 Астразенека Аб Химические соединения
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
DE602006015291D1 (de) * 2005-03-04 2010-08-19 Little Island Co Cork Hiv-inhibierende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidine
WO2006123113A2 (fr) 2005-05-16 2006-11-23 Astrazeneca Ab Composes chimiques
CN101248051B (zh) 2005-05-26 2013-07-17 泰博特克药品有限公司 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN101355939A (zh) * 2005-10-06 2009-01-28 马萨诸塞大学 用于抑制hiv复制的新物质的组合物和合成
TW200800963A (en) 2005-10-28 2008-01-01 Astrazeneca Ab Chemical compounds
WO2007082878A1 (fr) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Dérivés d'aminophényle en tant que nouveaux inibiteurs d'histone désacétylase
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
CA2635015C (fr) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Derive d'indolyl-alkyl-amino substitues en tant qu'inhibiteurs d'histone desacetylase
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
MX2008012576A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
DK2004641T3 (da) 2006-03-30 2011-01-24 Tibotec Pharm Ltd HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
MX2008015686A (es) 2006-06-06 2009-01-12 Tibotec Pharm Ltd Procedimiento para preparar formulaciones secadas por aspersion de etravirina.
NZ573757A (en) 2006-06-19 2011-11-25 Alpharma Inc Coated multilayer oral dosage forms of naltrexone hydrochloride
EP2073797A2 (fr) * 2006-10-11 2009-07-01 Alpharma, Inc. Compositions pharmaceutiques
ES2624593T3 (es) 2006-12-06 2017-07-17 Janssen Sciences Ireland Uc Sal de hidrobromuro de un compuesto anti-VIH.
BRPI0720858B8 (pt) * 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
ES2618057T3 (es) * 2006-12-29 2017-06-20 Janssen Sciences Ireland Uc Pirimidinas 5,6-sustituidas inhibidoras del VIH
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2009079521A1 (fr) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Composition pharmaceutique
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
BRPI0908637B8 (pt) 2008-05-21 2021-05-25 Ariad Pharma Inc composto e composição farmacêutica do mesmo
MX382352B (es) 2008-06-27 2025-03-13 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos.
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US20100137313A1 (en) * 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
ES2612485T3 (es) 2009-03-30 2017-05-17 Janssen Sciences Ireland Uc Co-cristal de etravirina y nicotinamida
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
WO2010131118A2 (fr) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Formes polymorphes d'étravirine et leurs procédés de préparation
US20110196156A1 (en) 2009-06-22 2011-08-11 Mukund Keshav Gurjar Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
WO2011017079A1 (fr) 2009-07-27 2011-02-10 Teva Pharmaceutical Industries Ltd. Procédé de préparation et de purification d'etravirine et intermédiaires de celui-ci
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
DK2576541T3 (en) 2010-06-04 2016-05-30 Hoffmann La Roche Aminopyrimidine AS LRRK2 MODULATORS
EP2584901A4 (fr) 2010-06-28 2013-10-09 Hetero Research Foundation Procédé de préparation d'intermédiaire de l'étravirine et de polymorphes de l'étravirine
NZ607845A (en) 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
CA2812061A1 (fr) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies
CA2815858C (fr) 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Composes heterocycliques et leurs utilisations
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
SI2638031T1 (en) 2010-11-10 2018-02-28 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
PL2702045T3 (pl) 2011-04-26 2018-04-30 Mylan Laboratories Ltd. Nowy sposób sporządzania Etrawiryny
EP2704572B1 (fr) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
WO2012170647A1 (fr) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Procédé pour la préparation d'étravirine et intermédiaires dans la synthèse de celle-ci
EP2748166B1 (fr) 2011-08-23 2018-07-11 Asana BioSciences, LLC Composés de pyrimido-pyridazinone et leurs procédés d'utilisation
WO2013059572A1 (fr) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Procédé de préparation d'etravarine et produits intermédiaires utiles dans la synthèse de ce composé
EP2770830A4 (fr) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc Méthodes de traitement d'une maladie ou d'une affection associée à la tyrosine-kinase btk (bruton's tyrosine kinase)
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (fr) 2012-11-08 2014-05-15 Universiteit Antwerpen Nouveaux composés anti-vih
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014094176A1 (fr) 2012-12-21 2014-06-26 Oncozyme Pharma Inc. Utilisations et méthodes concernant le traitement de maladies ou d'affections hépatiques
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formes et compositions d'un inhibiteur d'erk
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
US20190008868A1 (en) 2017-04-28 2019-01-10 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4694009A (en) * 1984-06-25 1987-09-15 Ciba-Geigy Corporation Pesticidal compositions
CH676712A5 (fr) 1988-03-31 1991-02-28 Mitsubishi Chem Ind
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (fr) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyle-n-arylpyrimidinamines et leurs derives
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
US6200977B1 (en) 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
EE04850B1 (et) * 1998-03-27 2007-06-15 Janssen Pharmaceutica N.V. Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku
EP0945442A1 (fr) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Dérivés de pyrimidine trisubstitués
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
KR100658489B1 (ko) * 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines

Also Published As

Publication number Publication date
UA70966C2 (uk) 2004-11-15
DE69941934D1 (de) 2010-03-04
LTC1002795I2 (lt) 2021-06-10
NO318801B1 (no) 2005-05-09
US8530655B2 (en) 2013-09-10
LTPA2008016I1 (lt) 2021-04-26
NL300373I1 (nl) 2009-03-02
LU91528I9 (fr) 2019-01-02
HRP20010161B1 (en) 2009-03-31
EE200100252A (et) 2002-10-15
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
NL300373I2 (nl) 2009-04-01
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
NO2021015I1 (no) 2021-03-29
EP1270560B1 (fr) 2010-01-13
HUP0104177A2 (hu) 2002-03-28
EP1002795B1 (fr) 2003-03-05
US8003789B2 (en) 2011-08-23
KR100658489B1 (ko) 2006-12-18
PL204427B1 (pl) 2010-01-29
BG105418A (en) 2001-11-30
SK6032001A3 (en) 2002-01-07
HU227453B1 (en) 2011-06-28
DE122009000003I1 (de) 2009-05-20
OA11674A (en) 2005-01-12
HK1048817B (en) 2010-04-09
ATE233740T1 (de) 2003-03-15
EP1270560A1 (fr) 2003-01-02
AU762523B2 (en) 2003-06-26
BRPI9915552B8 (pt) 2021-05-25
BR9915552A (pt) 2001-08-14
US6878717B2 (en) 2005-04-12
EA200100536A1 (ru) 2002-02-28
EP1002795A1 (fr) 2000-05-24
HRP20080359A2 (en) 2008-12-31
NZ511116A (en) 2003-08-29
CN1322198A (zh) 2001-11-14
NO20011696D0 (no) 2001-04-04
AU762523C (en) 2004-02-12
HU230394B1 (hu) 2016-04-28
CA2350801A1 (fr) 2000-05-18
EA004049B1 (ru) 2003-12-25
SK287269B6 (sk) 2010-05-07
ZA200103769B (en) 2002-08-12
IL169949A (en) 2011-02-28
SI1002795T1 (en) 2003-10-31
PL347586A1 (en) 2002-04-08
NO2009003I1 (no) 2009-03-09
HUP0104177A3 (en) 2003-01-28
NO2009003I2 (no) 2010-06-07
IL143023A0 (en) 2002-04-21
MY121108A (en) 2005-12-30
US7037917B2 (en) 2006-05-02
ES2338760T3 (es) 2010-05-12
CA2350801C (fr) 2008-05-20
AU6200899A (en) 2000-05-29
CY2008021I2 (el) 2010-07-28
DE69905683T2 (de) 2004-03-18
ID28376A (id) 2001-05-17
NO20011696L (no) 2001-04-04
KR20010075235A (ko) 2001-08-09
BG65103B1 (bg) 2007-02-28
CY2008021I1 (el) 2010-07-28
US20040039005A1 (en) 2004-02-26
CN1214013C (zh) 2005-08-10
CZ301367B6 (cs) 2010-02-03
CZ20011533A3 (cs) 2001-10-17
PT1002795E (pt) 2003-07-31
HK1048817A1 (en) 2003-04-17
AR024227A1 (es) 2002-09-25
JP3635238B2 (ja) 2005-04-06
HRP20010161B9 (hr) 2014-10-24
HRP20010161A2 (en) 2002-02-28
AU2011200708A1 (en) 2011-03-10
WO2000027825A1 (fr) 2000-05-18
EE05086B1 (et) 2008-10-15
US20110263625A1 (en) 2011-10-27
ES2193664T3 (es) 2003-11-01
ATE455107T1 (de) 2010-01-15
JP2002529456A (ja) 2002-09-10
US20080176880A1 (en) 2008-07-24
US20050288278A1 (en) 2005-12-29
TR200101306T2 (tr) 2001-10-22
HRP20080359B1 (hr) 2016-01-01
FR09C0004I2 (fr) 2010-06-11
HK1025330A1 (en) 2000-11-10
TWI238161B (en) 2005-08-21
FR09C0004I1 (fr) 2009-02-27
BR9915552B1 (pt) 2013-11-19
AP1683A (en) 2006-11-29

Similar Documents

Publication Publication Date Title
LU91528I2 (fr) "Etravirine sous toutes formes couvertes par le brevet de base"
FR2767350B1 (fr) Verrou fonctionnant sous l'action de la pesanteur
EP1074769A4 (fr) Structure d'etancheite
FR2760102B1 (fr) Autodirecteur orientable
EP1242050A4 (fr) Stimulation de l'angiogen se par l'utilisation de survivine
EP1153612A4 (fr) Potentialisateurs d'agent anticancereux
DE69926606D1 (de) Plazentaprotein 13
IT1299765B1 (it) Macinacaffe'
NO20005551D0 (no) 2"-deoksyhygromycinderivater
EP0998924A4 (fr) Agents antineoplastiques
NO996127L (no) 13-dihydro-3'-aziridino-antracykliner
ES1041880Y (es) Puya de picador.
ES1042496Y (es) "pilona sumible".
ITNO990011A0 (it) Asbest 2000
UA3109S (uk) Роз'єднувач
FR2800258B1 (fr) Grill - infrarouge - "giro" vertical
FI4330U1 (fi) Höyläpenkki
FI980765A0 (fi) Tillrinningsvask "skyddssystem"
UA2993S (uk) Тренажер "жим під кутом нагору"
UA3869S (uk) Емблема «телефортуна»
ES1044914Y (es) "bolsa perfeccionada"
IT248663Y1 (it) Struttura di supporto per l'esposizione di oggetti.
UA2410S (uk) Урна сміттєва
UA3710S (uk) Сидіння ортопедичне "кіпарис"
IT246105Y1 (it) Camino "doppio uso"